Department of Pediatrics A, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Pediatr Rheumatol Online J. 2023 Sep 1;21(1):93. doi: 10.1186/s12969-023-00880-1.
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in children; by definition, episodes occur every 2 to 8 weeks. However, in a subset of our patients, we noticed a higher frequency of attacks, of less than 2 weeks, which we refer to as extreme PFAPA (ePFAPA). This group consisted of patients who were extreme upon presentation of PFAPA, and those who became extreme after initiation of abortive corticosteroid treatment. We aimed to characterize demographic and clinical features of ePFAPA, including the two groups, and to compare them to patients with non-extreme PFAPA (nPFAPA).
The medical records of 365 patients with PFAPA who attended Schneider Children's Medical Center of Israel from March 2014 to April 2021 were reviewed. Patients with concomitant familial Mediterranean fever were excluded. Characteristics of the ePFAPA (including subgroups) and nPFAPA groups were compared using Wilcoxon rank sum, Pearson's chi-squared, and Fisher's exact tests.
Forty-seven patients (12.9%) were identified as having ePFAPA. Among patients with ePFAPA, compared to patients with nPFAPA, the median (interquartile range) age at disease onset was earlier: 1.5 years (0.7-2.5) vs. 2.5 years (1.5-4.0), P < 0.001; and diagnosis was younger: 2.6 years (2.0-3.6) vs. 4.5 years (3.0-6.2), P < 0.001. A higher proportion of patients with ePFAPA than nPFAPA were treated with colchicine prophylaxis (53% vs. 19%, P < 0.001), but symptoms and signs during flares did not differ significantly between these groups. Demographic and clinical characteristics were similar between patients with ePFAPA from presentation of PFAPA (22, 47% of those with ePFAPA) and ePFAPA from after corticosteroid treatment.
About half the patients categorized with ePFAPA syndrome already had extreme features upon presentation. Patients with ePFAPA compared to nPFAPA presented and were diagnosed at an earlier age.
周期性发热、口疮性口炎、咽炎和颈部淋巴结炎(PFAPA)综合征是儿童中最常见的周期性发热综合征;根据定义,每 2 至 8 周发作一次。然而,在我们的一部分患者中,我们注意到发作频率更高,不到 2 周一次,我们称之为极发性 PFAPA(ePFAPA)。该组包括最初表现为 ePFAPA 的患者,以及在开始使用缓解性皮质类固醇治疗后变得极发性的患者。我们旨在描述 ePFAPA 的人口统计学和临床特征,包括这两个组,并将其与非极发性 PFAPA(nPFAPA)患者进行比较。
回顾了 2014 年 3 月至 2021 年 4 月在以色列施耐德儿童医疗中心就诊的 365 例 PFAPA 患者的病历。排除了同时患有家族性地中海热的患者。使用 Wilcoxon 秩和检验、Pearson χ²检验和 Fisher 精确检验比较 ePFAPA(包括亚组)和 nPFAPA 组的特征。
确定 47 例(12.9%)患者为 ePFAPA。与 nPFAPA 患者相比,ePFAPA 患者疾病发作的中位(四分位距)年龄更早:1.5 岁(0.7-2.5)vs. 2.5 岁(1.5-4.0),P<0.001;诊断年龄更小:2.6 岁(2.0-3.6)vs. 4.5 岁(3.0-6.2),P<0.001。与 nPFAPA 患者相比,ePFAPA 患者中更倾向于使用秋水仙碱预防治疗(53% vs. 19%,P<0.001),但两组在发作期间的症状和体征无显著差异。从 PFAPA 出现(22 例,占 ePFAPA 的 47%)和皮质类固醇治疗后出现的 ePFAPA 患者的人口统计学和临床特征相似。
约一半归类为 ePFAPA 综合征的患者在出现时已经具有极端特征。与 nPFAPA 患者相比,ePFAPA 患者的发病和诊断年龄更早。